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Abstract
Objective: Musculoskeletal ultrasound (US) is frequently used in several rheumatology practices to detect
subclinical inflammation in patients with joint symptoms suspected for progression to inflammatory arthritis.
Evaluating the scientific basis for this specific US use, we performed this systematic literature review determining if
US features of inflammation are predictive for arthritis development and which US features are of additive value to
other, regularly used biomarkers.
Methods: Medical literature databases were systematically searched up to May 2017 for longitudinal studies
reporting on the association between greyscale (GSUS) and Power Doppler (PDUS) abnormalities and inflammatory
arthritis development in arthralgia patients. Quality of studies was assessed by two independent reviewers using a
set of 18 criteria. Studies were marked high quality if scored ≥ 80.6% (which is the median score). Best-evidence
synthesis was performed to determine the level of evidence (LoE). Positive and negative likelihood ratios (LR+, LR−)
were determined.
Results: Of 3061 unique references, six fulfilled inclusion criteria (three rated high quality), of which two reported
on the same cohort. Heterogeneity in arthralgia populations, various US machines and scoring systems hampered
the comparability of results. LoE for GSUS as predictor was limited and moderate for PDUS; LoE for the additive
value of GSUS and PDUS with other biomarkers was limited to moderate. Estimated LR+ values were mostly < 4
and LR− values > 0.5.
Conclusions: Data on the value of GSUS and PDUS abnormalities for predicting inflammatory arthritis development
are sparse. Although a potential benefit is not excluded, current LoE is limited to moderate. Future studies are
required, preferably performed in clearly defined, well-described arthralgia populations, using standardized US
acquisition protocols and scoring systems.
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Background
The development of rheumatoid arthritis (RA) is sup-
posed to consist of several stages: a) genetic risk factors
for RA; b) environmental risk factors for RA; c) systemic
autoimmunity associated with RA; d) symptoms without
clinical arthritis; e) unclassified arthritis (UA); f ) RA [1].
The phase of arthralgia preceding clinical arthritis (phase
d) is of particular interest since it is hypothesized that
disease-modifying treatment initiated in this phase might
result in better disease outcomes than when initiated in
the phases of UA and RA [2]. However, musculoskeletal
symptoms such as arthralgia are prevalent, and arthral-
gia is frequently not related to imminent RA. In order to
identify arthralgia patients at risk for RA, different strat-
egies can be undertaken, such as selecting arthralgia pa-
tients based on clinical features associated with RA
development, using autoantibody tests or imaging to de-
tect subclinical inflammation, or a combination of these.
Musculoskeletal ultrasound (US) is a frequently used
imaging modality as it is fast, easy to apply, and readily ac-
cessible. Although US is frequently used in patients pre-
senting with arthralgia (as also proposed in an algorithm
for the pragmatic use of US [3]) in several rheumatology
practices, we questioned what the scientific basis is to use
US as a predictor for future inflammatory arthritis devel-
opment. Therefore, we systematically studied the literature
to determine if US features of inflammation are predictive
for inflammatory arthritis development and, if so, to deter-
mine which US features are of additive value to other
regularly used biomarkers, with the ultimate goal of
obtaining evidence-based information on the value of US
in patients presenting with arthralgia.
Methods
Systematic literature search
The PRISMA guidelines were followed [4]. Search strat-
egies were built in collaboration with an experienced li-
brarian (WB) and executed in electronic medical literature
databases (Embase.com, Medline Ovid, Web of Science,
Scopus, Cochrane Central, Google Scholar) up to 11 May
2017 (complete searches in Additional file 1: File S1). Ref-
erence lists of the included papers were checked for add-
itional papers and unpublished and ongoing trials were
identified using the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP)
search portal (http://apps.who.int/trialsearch/) and Clini-
calTrials.gov (http://clinicaltrials.gov).
Selection of studies based on inclusion and exclusion
criteria
Two reviewers (SO, RvdB) assessed each title for suit-
ability for inclusion in this review, according to predeter-
mined inclusion and exclusion criteria. Next, abstracts
were retrieved for detailed review and, finally, full-text
papers were assessed if further information was required.
Papers not addressing the topic of interest were ex-
cluded and reasons for exclusion recorded.
From the total number of studies identified by the
database search, studies were included if the following
inclusion criteria were met: 1) investigation of subjects
without clinical arthritis, suffering from arthralgia, re-
gardless of rheumatoid factor (RF) and anti-citrullinated
protein antibody (ACPA) status or ACPA+ musculoskel-
etal symptoms; 2) investigation of small hand and/or feet
joints of subjects using US; 3) joints and/or tendons
were assessed for inflammatory features (GS synovial
hypertrophy and/or PDUS); 4) subjects were followed
prospectively; 5) development of (persistent) inflamma-
tory arthritis or RA was defined as outcome. Studies
about other inflammatory joint conditions, animal stud-
ies, reviews, letters to the editor, case reports, case series,
commentaries, guidelines, editorials, abstracts, study
populations < 18 years of age, and studies in languages
other than English, Dutch, and German were excluded.
Data extraction
The two reviewers independently assessed the full texts of
the included studies using a predefined sheet to extract
data about: 1) study population (number of patients, age,
gender, symptom duration); 2) follow-up period; 3) mus-
culoskeletal US equipment (producer, transducer, machine
setting, mode (GSUS/PDUS); 4) US acquisition (number
and type of examined joints, examined pathology, scoring
method, potential used cut-off); 5) longitudinal outcome.
Data from univariable analyses were extracted to an-
swer the first aim; data from multivariable analyses were
extracted to answer the second aim on added value.
Quality assessment and analyses
Due to heterogeneity of the studies, it was not possible
to perform meta-analyses and calculate pooled effect es-
timates. Therefore, we performed a best-evidence syn-
thesis based on the guidelines on systemic review of the
Cochrane Collaboration Back and Neck (CBN) Group
[5], a method summarizing the level of evidence (LoE)
in observational studies if study population, outcomes
and data analyses are heterogenic (Additional file 1:
Table S1). LoE is based on presence of statistical signifi-
cance, which depends on sample sizes, taking into ac-
count the quality of the studies. Quality of the studies
was evaluated by the two reviewers individually, using a
set of 18 criteria based on previous systematic reviews in
prognostic factors in the field of musculoskeletal disor-
ders [2, 6]. This list included seven criteria specifically
for the use of US, of which three were considered
mandatory (Additional file 1: Table S2). A study was
considered high quality if all three mandatory criteria
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were fulfilled and the total score was ≥ 80.6% (median of
quality scores obtained in this review).
Positive and negative likelihood ratios (LR+ and LR−,
respectively) and positive and negative predictive values
(PPV and NPV, respectively) were calculated based on
presented data regarding outcome (using the presented
follow-up duration (Table 1)) to evaluate the predictive
accuracy. Also, due to heterogeneity, no summary esti-
mates were calculated.
Results
Selection and inclusion of articles
In total, 5028 titles were identified and, after removing
duplicates, 3061 unique references were screened
(Additional file 1: Figure S1). After detailed review, six
full-text papers fulfilled the inclusion and exclusion cri-
teria (Table 1) [7–12], of which two studies reported on
the same cohort [10, 11]. One of them reports on di-
chotomous PDUS results only and the other presents
PDUS and GS synovial hypertrophy results for various
cut-offs.
Quality assessment
The two reviewers rated 108 items and agreed on 98
(91.6%); disagreement on items was solved by discussion
(Additional file 1: Table S3). All six included studies ful-
filled the three mandatory criteria. Median quality score
was 80.6% (range 61.1–83.3%). Two of the three
high-quality papers described the same cohort [8, 10, 11].
Study characteristics
The number of included patients varied between 80 and
379; the majority were female (69–83%) aged > 50 years.
None of the studies had stringent inclusion criteria with
respect to symptom constitution. The cohort described
in the papers by Nam et al. [10] and Rakieh et al. [11]
included ACPA+ patients with new onset musculoskel-
etal symptoms from primary care physician clinics and
the rheumatology early arthritis clinic in Leeds. In the
study of Van der Ven et al. [8], patients with inflamma-
tory joint complaints involving at least two joints in the
hands, feet, or shoulders for < 1 year which could not be
explained by other conditions were included if they had
also at least two of the following criteria: morning stiff-
ness for > 1 h, unable to clench a fist in the morning,
pain when shaking someone’s hand, pins and needles in
the fingers, difficulties wearing rings or shoes, family his-
tory of RA, and/or unexplained fatigue. In the paper by
Zufferey et al. [7], ACPA- and RF-negative patients with
polyarthralgia for > 6 weeks with an inflammatory or
mixed (mechanical and inflammatory) character referred
by their general practitioner or rheumatologist were in-
cluded. Van de Stadt et al. [12] recruited ACPA+ and/or
RF+ patients with arthralgia, defined as “non-traumatic
pain in any joint”, at rheumatology clinics in Amsterdam
after referral by their general practitioner. Patients pre-
senting with new-onset arthralgia to the Newcastle Early
Arthritis Clinic were included in the study by Pratt et al.
[9], but no description of arthralgia was provided.
Symptom duration at inclusion varied between 6 weeks
and 23 months (Table 1). Patients were followed for >
12 months in all studies (range 12–28 months). Three
studies included only ACPA+ and/or RF+ patients [10–
12]; one study only ACPA- and RF-negative patients [7]
and the remaining studies included both ACPA+ and/or
RF+ and arthralgia negative patients [8, 9].
Acquisition of ultrasound
US specifications are presented in Table 2. Three studies
used a transducer with 12 or 13 MHz as maximum [7, 9,
12]. Various US machines were used, various scoring
systems with various definitions of pathology were used
to grade synovitis [13–20], and the number of examined
joints varied (range 16–32). In one study only tender
joints were scanned [12]. Four studies reported on both
GS synovial hypertrophy and PDUS [8–10, 12], one only
on GS synovial hypertrophy [7], and one only on PDUS
[11]. Only one study scored the presence of tenosyno-
vitis (GSUS) [12]. All studies except one [10] used a
cut-off to define a positive “inflammation US score”, yet
the definitions varied (Table 2).
Two studies reported on inter-observer reliability,
which was moderate (kappa = 0.56 for GS synovial
hypertrophy) to substantial (kappa = 0.64 for PDUS) [9]
in one study, and fair (kappa = 0.22 for effusion) to mod-
erate (kappa = 0.47 for synovitis) and substantial (kappa
= 0.67 for PDUS) in another study [12], yet good in
terms of overall percentage agreement (88–92%).
Outcome
Outcome was defined as RA (ACR/EULAR 2010 criteria
[21]) in one study and (persistent) (inflammatory) arth-
ritis in the remaining five. Outcome was reached in 8.8–
50.0% of patients; frequency was lowest in ACPA-/
RF-negative populations and highest in ACPA+/RF+
populations. Duration until outcome was reached varied
between 7.9 and 18.3 months and was not specified in
two studies (Table 1).
LoE of GSUS and PDUS abnormalities as predictor for
arthritis development
The prevalence of different US features varied per pa-
tient group and cut-off used. For GS synovial hyper-
trophy it ranged from 11.6 (GSUS ≥ 2 in patients
without arthritis development) to 77.2% (GSUS ≥ 2 in
patients that developed arthritis); for PDUS from 6.3
(PDUS = 2 in patients without arthritis development) to
44.0% (PDUS ≥ 1 in patients that developed arthritis)
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(Table 2). The prevalence of tenosynovitis ranged from
6.1 (GSUS ≥ 2 in patients without arthritis development)
to 8.9% (GSUS ≥ 2 in patients with arthritis
development).
GS synovial hypertrophy
One high-quality and one low-quality study reported a
non-statistically significant association between GS syn-
ovial hypertrophy and arthritis development (HR 2.8
[95% CI 0.4–20.3] and (OR 1.41 [95% CI 0.54–3.65], re-
spectively) [10, 12]. One other high-quality study re-
ported a statistically significant association (OR 3.03
[95% CI: 1.69–5.41]) for a “positive US” defined as GSUS
≥ 2 and/or PDUS ≥ 1 [8]. Hence, LoE with regard to the
predictive value of GSUS is limited.
PDUS synovitis
Two high-quality studies reported a statistically signifi-
cant association between PDUS and arthritis develop-
ment (OR 3.12 [95% CI 1.61–6.03] [8], HR 1.88 [95% CI
1.07–3.29] [11]). The third high-quality study (per-
formed in the same cohort as [11]) reported a
non-statistically significant association (HR 1.6 [95% CI
0.9–3.2]) [10]; thus the statistically significant association
found in the first 100 patients was lost after inclusion of
additional patients. A low-quality study reported a
non-significant association as well (OR 1.54 [95% CI
0.67–3.54]) [12]. Hence, LoE with regard to the predict-
ive value of PDUS is moderate.
Tenosynovitis
One low-quality study evaluated tenosynovitis and found
no statistically significant association with arthritis de-
velopment (OR 1.50 [95% CI 0.44–5.11]) [12]. Hence,
LoE with regard to the predictive value of tenosynovitis
is insufficient.
LoE of GSUS and PDUS abnormalities being additive to
other biomarkers
Three studies investigated the association of GS synovial
hypertrophy with arthritis development, correcting for
different biomarkers (Table 1). Two low-quality studies
reported statistically significant associations of GS syn-
ovial hypertrophy and arthritis development (OR 4.91
[95% CI 2.32–10.4]), OR 7.45 [95% CI 1.19–42.8], and
OR 10.1 [95% CI 1.1–49] [7, 9]. One high-quality study
reported a statistically significant association of a “posi-
tive US” (GSUS ≥ 2 and/or PDUS ≥ 1; OR 2.65 [95% CI
1.44–4.88]) [8]. Hence, LoE with regard to the question
of whether GS synovial hypertrophy may have value in
predicting arthritis development, additive to regularly
assessed biomarkers, is moderate.
Likewise, two studies performed multivariable analysis
with PDUS. After correction for (different) biomarkers
(Table 1), one high-quality study reported a statistically
significant association (OR 3.44 [95% CI 1.71–6.95]) [8].
The other high-quality study reported a non-significant
association (HR 1.51 [95% CI 0.83–2.74]) [11]. Hence,
LoE of the value of PDUS in addition to other bio-
markers is limited.
The value of tenosynovitis (GS/PD) in addition to
other biomarkers was not investigated.
Positive and negative likelihood ratios and absolute risks
Calculated LRs varied and confidence intervals (CIs)
were wide. For GS synovial hypertrophy, LR+ ranged
from 1.27–3.48 and LR− ranged from 0.36–0.95. For
PDUS, LR+ ranged from 1.42–4.16 and LR− ranged
from 0.63–0.92 (Fig. 1 and Additional file 1: Table S4).
Predictive values are directly proportional to disease
prevalence. Percentages of patients that developed arth-
ritis varied between 8.8 and 50%; thus, prior risks for not
progressing were 50–91.2%. We calculated the increase in
the absolute risks of inflammatory arthritis provided by
US-detected abnormalities by comparing PPV and NPV
with prior risks (Additional file 1: Table S4). Overall, PPVs
were low or moderate (23.5–71.9% for GS synovial hyper-
trophy; 30.3–75% for PDUS) and the increase in absolute
risks in US-positive patients ranged from 5.8–29.2% (GS
synovial hypertrophy) and 6.9–33.1% (PDUS). NPVs were
higher (68.9–96.7% for GS synovial hypertrophy; 58.2–
85.1% for PDUS), but the gain in relation to prior risk of
not progressing to arthritis was relatively small (0.8–12.5%
for GS synovial hypertrophy; 2.9–13.9% for PDUS). Thus,
NPVs were largely explained by prior risks of not develop-
ing inflammatory arthritis.
Discussion
The aim of this systematic literature review was to deter-
mine if US features of inflammation are predictive for
inflammatory arthritis development and, if so, which US
features are of additive value to other regularly used bio-
markers. LoE for GS synovial hypertrophy as predictor
for arthritis was limited and moderate for PDUS. LoE
for the additive value of GS synovial hypertrophy and
PDUS with other regularly used biomarkers was limited
to moderate. Additionally, there was insufficient data on
the value of US-detected tenosynovitis. Thus, there is a
discrepancy between the frequent use of US in arthralgia
patients to search for subclinical inflammation (which, if
present, is generally considered a sign of imminent RA)
in several rheumatology practices and the absence of
strong scientific evidence on its prognostic value.
The limited/moderate LoE might be explained by rela-
tively low number of studies and the presence of differ-
ent types of heterogeneity. Only six studies were
included in this systematic literature review, of which
two described the same cohort. The number of included
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patients per study was rather low, influencing the power
to achieve statistical significance. Furthermore, heteroge-
neous arthralgia populations (seropositive arthralgia,
seronegative arthralgia, ACPA+ patients with unspecific
musculoskeletal (MSK) symptoms) were studied in dif-
ferent settings (primary and/or secondary care), with
slightly differently defined outcomes ((persistent) (in-
flammatory) arthritis, RA), contributing to the various
ranges of frequencies of outcome (8.8–50%).
Moreover, the US acquisition protocol, definitions of
pathology, and scoring systems varied, although all
followed internationally recognized recommendations and
scoring systems [13–20]. Only very recently, EULAR/
OMERACT published a standardized, consensus-based
semi-quantitative scoring system for GS synovial hyper-
trophy and PDUS (separately and combined) [24, 25], but
this was not available when the studies included in this re-
view were executed.
Other sources of heterogeneity were the selection of
assessed joints, whether they were scanned from a volar
or dorsal aspect, and the fact that different machines were
used. It is known that the diverse machines have a wide
variation in sensitivity to pick up inflammation, especially
with regard to Doppler modalities [26]. Three studies used
a transducer with 12 or 13 MHz as maximum, while
higher frequencies are recommended especially for scan-
ning small hand joints. Ideally, in order to arrive at a
higher LoE, future studies should be performed in more
homogeneous arthralgia populations (e.g., fulfilling the
EULAR definition of arthralgia at risk for RA [27]), using
the same scan and scorings protocols (e.g., EULAR/
OMERACT [24, 25]).
Another issue is the definition of a “positive US”. Differ-
ent cut-offs were applied and none of the studies included
information on US findings in healthy volunteers. It has
been shown that a cut-off incorporating such findings in-
creased the prognostic value for the use of MRI in arthral-
gia patients [28]. Also US “inflammatory features” can be
detected in healthy volunteers, especially in certain joints
and increasing with age [29–36]. Whether incorporating
age-dependent US reference values might increase the
predictive value of US remains to be determined.
Fig. 1 Forest plots of LR+ and LR− for GSUS (a, b) and PDUS (c, d). LR+ = positive likelihood ratio; LR− = negative likelihood ratio. GSUS greyscale
ultrasound, PDUS power Doppler ultrasound. Some studies used different cut-offs and are presented two or three times in this figure. Pratt: a
GSUS sum score≥ 2; b GSUS sum score/6 joints (worst hand) ≥ 2; c GSUS number of joints ≥ 1: ≥ 3; d PDUS sum score≥ 1; e PDUS number of
joints ≥1: ≥ 2. Zufferey: a B-mode score > 8 (of total possible score of 66); b ≥ 2 joints (of total number of 22 joints) with grade≥ 2 synovitis [18].
Likelihood ratio values between 0 and 1 decrease the probability of disease; values greater than 1 increase the probability of disease. An LR of 1
does not influence the probability. In general, an LR+ of 2 results in an approximate change of + 15% in post-probability; an LR+ of 5 in an
approximate change of + 30% and an LR+ of 10 in an approximate change of + 45%. An LR− of 0.5 results in an approximate change of − 15% in
post-probability; an LR− of 0.2 in an approximate change of − 30% and an LR− of 10 in an approximate change of − 45%. These estimations are
accurate for pre-test probabilities between 10% and 90% [23]
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There was insufficient data to determine whether
US-detected tenosynovitis is an (important) predictor of
arthritis development, which is the case for MRI-detected
subclinical tenosynovitis (which is an even stronger pre-
dictor than MRI-detected subclinical synovitis or bone
marrow edema) [37]. Therefore, the potential of
US-detected tenosynovitis requires further investigation.
We sought to explore the value of US abnormalities in
addition to other frequently used predictors of arthritis
development. Some studies performed multivariable
analyses but adjusted for different variables; hence, the
results of these multivariable analyses could not be dir-
ectly compared. Further studies on this subject are
needed, also using methods such as net reclassification
index.
Best-level evidence synthesis focuses on statistical sig-
nificance. Since this is not directly applicable for clinical
practice, we also expressed prognostic accuracy using
LRs. Estimated LR+ values were mostly < 4 and LR−
values > 0.5, some with wide CIs, indicating that the
post-test probability was altered to only a small degree.
This was also observed when we calculated increases in
absolute risks (comparing pre-test with observed
post-test risks). Although absolute NPVs were higher
than PPVs, and seemingly more informative, this was
caused by the prior risks, which were relatively low. Our
comparison of pre-test and post-test risks suggested that
US is slightly more helpful in “ruling in” than “ruling
out” imminent inflammatory arthritis.
Conclusions
US is frequently used in arthralgia patients in several
rheumatologic practices, and although some studies have
suggested a potential benefit of US, the current LoE is lim-
ited to moderate at best, due to heterogeneity of studies
and lack of replication. Yet, there is a strong need for val-
idation of results in future US studies, preferably per-
formed in clearly defined, well-described arthralgia
patients. The EULAR definition of arthralgia suspicious
for progression to RA might be used to this end.
Additional file
Additional file 1: Overview of literature research, Best-evidence synthesis,
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